Inhibikase Therapeutics (IKT)
(Real Time Quote from BATS)
$1.96 USD
+0.42 (27.27%)
Updated May 15, 2024 03:32 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
IKT 1.96 +0.42(27.27%)
Will IKT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IKT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IKT
Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now
New Strong Buy Stocks for February 13th
IKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for February 8th
New Strong Buy Stocks for February 8th
New Strong Buy Stocks for February 6th
Other News for IKT
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
Inhibikase announces request for withdrawal of S-1 registration statement
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
Inhibikase Therapeutics announces final pre-IND meeting outcomes for IkT-001Pro
Inhibikase Therapeutics Faces Legal Dispute Amid Clinical Trials